Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
12.0M
Short interest
settlement 2026-10-15
5.0
Days to cover
+0.6 days vs prior
43.1%
Short share of volume
2026-10-28
15
Fails to deliver
settlement 2026-09-24
Wed 4 Nov
Next earnings
estimated date
-$28.9M
Insider flow, 90 days
0 buys, 48 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ADPT is 11,991,988 shares, down 1,497,593 shares over the last month. Over the last 48 readings it ranged from 7,645,147 shares (15 June 2026) to 13,489,581 shares (15 September 2026). At the reported average volume of 2.4M shares a day that is 5.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/adpt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 11,991,988 | +1.3% | 2,383,521 | 5.03 |
| 2026-09-30 | 11,843,887 | -12.2% | 2,674,025 | 4.43 |
| 2026-09-15 | 13,489,581 | +15.2% | 1,708,828 | 7.89 |
| 2026-08-31 | 11,712,796 | -12.1% | 1,839,973 | 6.37 |
| 2026-08-14 | 13,323,767 | +6.7% | 2,329,412 | 5.72 |
| 2026-07-31 | 12,490,395 | +9.6% | 2,844,419 | 4.39 |
| 2026-07-15 | 11,396,387 | +0.4% | 2,645,741 | 4.31 |
| 2026-06-30 | 11,352,839 | +48.5% | 5,086,171 | 2.23 |
| 2026-06-15 | 7,645,147 | -7.2% | 2,708,847 | 2.82 |
| 2026-05-29 | 8,240,744 | -7.4% | 1,606,754 | 5.13 |
| 2026-05-15 | 8,897,341 | +5.4% | 1,955,224 | 4.55 |
| 2026-04-30 | 8,439,712 | -1.3% | 1,216,819 | 6.94 |
| 2026-04-15 | 8,551,420 | -0.1% | 1,936,987 | 4.41 |
| 2026-03-31 | 8,558,955 | -7.4% | 2,110,288 | 4.06 |
| 2026-03-13 | 9,247,322 | +4.2% | 2,530,853 | 3.65 |
| 2026-02-27 | 8,877,604 | -3.4% | 1,364,625 | 6.51 |
| 2026-02-13 | 9,193,089 | +1.8% | 2,153,033 | 4.27 |
| 2026-01-30 | 9,033,105 | +0.1% | 1,623,391 | 5.56 |
| 2026-01-15 | 9,021,329 | +3.0% | 2,247,383 | 4.01 |
| 2025-12-31 | 8,760,209 | -10.1% | 1,975,967 | 4.43 |
| 2025-12-15 | 9,742,510 | -6.3% | 3,315,759 | 2.94 |
| 2025-11-28 | 10,403,303 | +0.3% | 2,775,932 | 3.75 |
| 2025-11-14 | 10,368,382 | +15.1% | 2,082,975 | 4.98 |
| 2025-10-31 | 9,010,315 | -0.2% | 1,544,106 | 5.84 |
| 2025-10-15 | 9,027,063 | -5.9% | 1,821,457 | 4.96 |
| 2025-09-30 | 9,588,547 | +2.6% | 2,062,003 | 4.65 |
| 2025-09-15 | 9,344,814 | +10.8% | 1,875,530 | 4.98 |
| 2025-08-29 | 8,431,307 | -5.8% | 1,737,815 | 4.85 |
| 2025-08-15 | 8,945,230 | -9.9% | 2,636,846 | 3.39 |
| 2025-07-31 | 9,929,497 | +2.5% | 1,500,007 | 6.62 |
| 2025-07-15 | 9,686,697 | -4.3% | 1,783,556 | 5.43 |
| 2025-06-30 | 10,126,395 | +13.4% | 3,157,380 | 3.21 |
| 2025-06-13 | 8,927,326 | -7.4% | 1,192,070 | 7.49 |
| 2025-05-30 | 9,639,924 | +5.9% | 1,216,277 | 7.93 |
| 2025-05-15 | 9,102,374 | -0.5% | 3,606,959 | 2.52 |
| 2025-04-30 | 9,144,237 | -7.6% | 1,672,951 | 5.47 |
| 2025-04-15 | 9,894,691 | -2.2% | 2,691,617 | 3.68 |
| 2025-03-31 | 10,121,172 | +6.7% | 2,094,602 | 4.83 |
| 2025-03-14 | 9,488,437 | +9.5% | 2,266,629 | 4.19 |
| 2025-02-28 | 8,663,017 | -1.3% | 1,560,337 | 5.55 |
| 2025-02-14 | 8,775,706 | +2.9% | 1,622,042 | 5.41 |
| 2025-01-31 | 8,530,375 | -1.5% | 1,358,325 | 6.28 |
| 2025-01-15 | 8,656,445 | -5.8% | 1,679,207 | 5.16 |
| 2024-12-31 | 9,189,671 | +1.8% | 1,009,701 | 9.10 |
| 2024-12-13 | 9,030,599 | -5.7% | 1,147,572 | 7.87 |
| 2024-11-29 | 9,579,850 | +16.8% | 1,774,768 | 5.40 |
| 2024-11-15 | 8,203,880 | -8.5% | 1,233,782 | 6.65 |
| 2024-10-31 | 8,963,251 | -5.4% | 828,666 | 10.82 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of ADPT volume is 43.1%, down 25.9 points over the last five sessions. Over the last 30 readings it ranged from 20.8% (15 October 2026) to 70.9% (1 October 2026). The latest reading is 2.7 points below the 30-session average of 45.8%, on 1.2M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 515K | 1.2M | 43.1% | 6 |
| 2026-10-27 | 243K | 563K | 43.2% | 1 |
| 2026-10-26 | 189K | 403K | 47.0% | 110 |
| 2026-10-23 | 398K | 788K | 50.5% | 1,225 |
| 2026-10-22 | 287K | 438K | 65.4% | 31 |
| 2026-10-21 | 538K | 779K | 69.0% | 449 |
| 2026-10-20 | 170K | 413K | 41.3% | 284 |
| 2026-10-19 | 194K | 407K | 47.7% | 400 |
| 2026-10-16 | 315K | 719K | 43.8% | 59 |
| 2026-10-15 | 160K | 771K | 20.8% | 176 |
| 2026-10-14 | 452K | 816K | 55.4% | 0 |
| 2026-10-13 | 340K | 706K | 48.2% | 17 |
| 2026-10-12 | 663K | 1.6M | 42.8% | 6,501 |
| 2026-10-09 | 308K | 595K | 51.8% | 187 |
| 2026-10-08 | 353K | 707K | 49.9% | 1,205 |
| 2026-10-07 | 286K | 651K | 43.8% | 6,272 |
| 2026-10-06 | 300K | 995K | 30.2% | 3,587 |
| 2026-10-05 | 196K | 460K | 42.5% | 1,018 |
| 2026-10-02 | 267K | 569K | 46.8% | 0 |
| 2026-10-01 | 3.0M | 4.2M | 70.9% | 3,992 |
| 2026-09-30 | 180K | 353K | 51.0% | 0 |
| 2026-09-29 | 883K | 1.4M | 64.3% | 6 |
| 2026-09-28 | 436K | 1.1M | 39.4% | 54,818 |
| 2026-09-25 | 246K | 686K | 35.9% | 21 |
| 2026-09-24 | 315K | 1.2M | 26.5% | 1,921 |
| 2026-09-23 | 166K | 316K | 52.4% | 0 |
| 2026-09-22 | 618K | 2.0M | 30.8% | 0 |
| 2026-09-21 | 213K | 552K | 38.6% | 5,300 |
| 2026-09-18 | 459K | 985K | 46.6% | 845 |
| 2026-09-17 | 478K | 1.4M | 35.1% | 909 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 24 September 2026, the fails-to-deliver balance in ADPT is 15 shares, down 6,464 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (31 December 2025) to 974,254 shares (16 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-24 | 15 | $27.89 | $418 |
| 2026-09-08 | 6,479 | $24.28 | $157K |
| 2026-08-27 | 153 | $26.16 | $4K |
| 2026-08-24 | 480 | $25.99 | $12K |
| 2026-08-14 | 2,591 | $24.46 | $63K |
| 2026-08-11 | 230 | $25.45 | $6K |
| 2026-08-04 | 975 | $23.11 | $23K |
| 2026-07-27 | 137 | $22.27 | $3K |
| 2026-07-22 | 23 | $22.58 | $519 |
| 2026-07-20 | 684 | $22.92 | $16K |
| 2026-07-17 | 57 | $22.10 | $1K |
| 2026-06-30 | 3,100 | $21.40 | $66K |
| 2026-06-18 | 84 | $16.78 | $1K |
| 2026-06-12 | 234 | $18.73 | $4K |
| 2026-04-15 | 1,691 | $14.53 | $25K |
| 2026-04-01 | 53,074 | $13.88 | $737K |
| 2026-03-30 | 173,482 | $12.41 | $2.2M |
| 2026-03-16 | 974,254 | $13.17 | $12.8M |
| 2026-02-27 | 6,515 | $16.46 | $107K |
| 2026-02-10 | 13,608 | $15.86 | $216K |
| 2026-02-03 | 12,827 | $18.39 | $236K |
| 2026-02-02 | 5,928 | $18.50 | $110K |
| 2026-01-14 | 1,965 | $18.07 | $36K |
| 2026-01-12 | 1,943 | $15.76 | $31K |
| 2026-01-08 | 125 | $16.73 | $2K |
| 2026-01-06 | 3,949 | $16.17 | $64K |
| 2025-12-31 | 2 | $16.42 | $33 |
| 2025-12-26 | 1,023 | $16.68 | $17K |
| 2025-12-24 | 4,569 | $16.75 | $77K |
| 2025-12-23 | 870 | $17.41 | $15K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ADPT reported 48 open-market sells worth $28.9M in the last 90 days and no open-market buys. Latest filing: RUBINSTEIN JULIE (President and COO) on 2026-10-26.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-26 | RUBINSTEIN JULIE | President and COO | Sell | 3K | $26.30 | $89K | 378K |
| 2026-10-26 | RUBINSTEIN JULIE | President and COO | Sell | 9K | $25.94 | $221K | 381K |
| 2026-10-26 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-23 | RUBINSTEIN JULIE | President and COO | Sell | 7K | $25.28 | $187K | 378K |
| 2026-10-23 | RUBINSTEIN JULIE | President and COO | Sell | 5K | $24.50 | $110K | 385K |
| 2026-10-23 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-22 | RUBINSTEIN JULIE | President and COO | Sell | 2K | $25.29 | $43K | 378K |
| 2026-10-22 | RUBINSTEIN JULIE | President and COO | Sell | 10K | $24.38 | $248K | 380K |
| 2026-10-22 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-21 | RUBINSTEIN JULIE | President and COO | Sell | 6K | $25.57 | $150K | 378K |
| 2026-10-21 | RUBINSTEIN JULIE | President and COO | Sell | 6K | $25.25 | $151K | 384K |
| 2026-10-21 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-20 | RUBINSTEIN JULIE | President and COO | Sell | 100 | $24.85 | $2K | 378K |
| 2026-10-20 | RUBINSTEIN JULIE | President and COO | Sell | 12K | $24.53 | $289K | 378K |
| 2026-10-20 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-19 | RUBINSTEIN JULIE | President and COO | Sell | 12K | $24.05 | $286K | 378K |
| 2026-10-19 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-16 | RUBINSTEIN JULIE | President and COO | Sell | 300 | $25.45 | $8K | 378K |
| 2026-10-16 | RUBINSTEIN JULIE | President and COO | Sell | 12K | $24.21 | $280K | 378K |
| 2026-10-16 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-15 | RUBINSTEIN JULIE | President and COO | Sell | 12K | $25.61 | $304K | 378K |
| 2026-10-15 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-14 | RUBINSTEIN JULIE | President and COO | Sell | 5K | $25.82 | $132K | 378K |
| 2026-10-14 | RUBINSTEIN JULIE | President and COO | Sell | 7K | $25.57 | $173K | 383K |
| 2026-10-14 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-13 | RUBINSTEIN JULIE | President and COO | Sell | 12K | $25.50 | $303K | 378K |
| 2026-10-13 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-12 | RUBINSTEIN JULIE | President and COO | Sell | 3K | $26.07 | $70K | 378K |
| 2026-10-12 | RUBINSTEIN JULIE | President and COO | Sell | 9K | $25.35 | $233K | 381K |
| 2026-10-12 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-09 | RUBINSTEIN JULIE | President and COO | Sell | 12K | $26.41 | $314K | 378K |
| 2026-10-09 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-08 | RUBINSTEIN JULIE | President and COO | Sell | 12K | $25.66 | $305K | 378K |
| 2026-10-08 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-07 | RUBINSTEIN JULIE | President and COO | Sell | 12K | $26.40 | $314K | 378K |
| 2026-10-07 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-06 | BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell | 6K | $30.00 | $193K | 389K |
| 2026-10-06 | RUBINSTEIN JULIE | President and COO | Sell | 499 | $30.53 | $15K | 378K |
| 2026-10-06 | RUBINSTEIN JULIE | President and COO | Sell | 901 | $29.71 | $27K | 378K |
| 2026-10-06 | RUBINSTEIN JULIE | President and COO | Sell | 1K | $28.21 | $31K | 379K |
| 2026-10-06 | RUBINSTEIN JULIE | President and COO | Sell | 9K | $27.36 | $257K | 380K |
| 2026-10-06 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-05 | RUBINSTEIN JULIE | President and COO | Sell | 5K | $29.67 | $154K | 378K |
| 2026-10-05 | RUBINSTEIN JULIE | President and COO | Sell | 7K | $28.82 | $193K | 383K |
| 2026-10-05 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-02 | RUBINSTEIN JULIE | President and COO | Sell | 12K | $28.13 | $334K | 378K |
| 2026-10-02 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-10-01 | LO FRANCIS | Chief People Officer | Exercise or conversion | 9K | $8.12 | $76K | 248K |
| 2026-10-01 | LO FRANCIS | Chief People Officer | Sell | 19K | $28.61 | $535K | 221K |
| 2026-10-01 | LO FRANCIS | Chief People Officer | Sell | 8K | $27.52 | $223K | 240K |
| 2026-10-01 | LO FRANCIS | Chief People Officer | Exercise or conversion | 9K | $3.99 | $37K | 238K |
| 2026-10-01 | LO FRANCIS | Chief People Officer | Exercise or conversion | 8K | $8.46 | $68K | 229K |
| 2026-10-01 | RUBINSTEIN JULIE | President and COO | Sell | 6K | $28.56 | $166K | 378K |
| 2026-10-01 | RUBINSTEIN JULIE | President and COO | Sell | 6K | $27.57 | $168K | 384K |
| 2026-10-01 | RUBINSTEIN JULIE | President and COO | Exercise or conversion | 12K | $12.14 | $144K | 390K |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Sell | 8K | $28.57 | $225K | 221K |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Sell | 108K | $28.02 | $3.0M | 229K |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Exercise or conversion | 23K | $8.12 | $190K | 336K |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Exercise or conversion | 16K | $3.99 | $62K | 313K |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Exercise or conversion | 13K | $8.46 | $113K | 297K |
| 2026-09-16 | LO FRANCIS | Chief People Officer | Exercise or conversion | 53K | $12.14 | $645K | 284K |
| 2026-09-15 | BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell | 1K | $27.00 | $32K | 396K |
| 2026-08-31 | OWEN KATEY EINTERZ | Director | Gift | 13K | price not stated in the filing | not stated | 66K |
| 2026-08-26 | OWEN KATEY EINTERZ | Director | Sell | 10K | $26.00 | $250K | 79K |
| 2026-08-18 | HERSHBERG ROBERT | Director | Sell | 16K | $24.41 | $382K | 47K |
| 2026-08-18 | HERSHBERG ROBERT | Director | Sell | 15K | $24.39 | $366K | 62K |
| 2026-08-18 | HERSHBERG ROBERT | Director | Exercise or conversion | 15K | $6.32 | $95K | 77K |
| 2026-08-18 | ROBINS CHAD M | CEO and Chairman | Sell | 204 | $25.14 | $5K | 2.2M |
| 2026-08-18 | ROBINS CHAD M | CEO and Chairman | Sell | 278K | $24.48 | $6.8M | 2.2M |
| 2026-08-18 | ROBINS CHAD M | CEO and Chairman | Exercise or conversion | 279K | $6.55 | $1.8M | 2.5M |
| 2026-08-17 | ROBINS CHAD M | CEO and Chairman | Sell | 3K | $25.57 | $65K | 2.2M |
| 2026-08-17 | ROBINS CHAD M | CEO and Chairman | Sell | 319K | $25.08 | $8.0M | 2.2M |
| 2026-08-17 | ROBINS CHAD M | CEO and Chairman | Exercise or conversion | 321K | $6.55 | $2.1M | 2.5M |
| 2026-08-17 | NEUPERT PETER M | Director | Sell | 70K | $25.16 | $1.8M | 131K |
| 2026-08-17 | NEUPERT PETER M | Director | Sell | 40K | $25.10 | $1.0M | 200K |
| 2026-08-17 | NEUPERT PETER M | Director | Sell | 15K | $25.23 | $378K | 240K |
| 2026-08-17 | NEUPERT PETER M | Director | Exercise or conversion | 15K | $6.32 | $95K | 255K |
| 2026-08-10 | BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell | 3K | $25.00 | $75K | 397K |
| 2026-07-30 | BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell | 1K | $24.00 | $31K | 400K |
| 2026-07-21 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 214K | $22.12 | $4.7M | 812K |
| 2026-07-21 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 279K | $21.72 | $6.1M | 1.0M |
| 2026-07-21 | ROBINS HARLAN S | Chief Scientific Officer | Exercise or conversion | 285K | $6.55 | $1.9M | 1.3M |
| 2026-07-16 | BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell | 5K | $23.00 | $115K | 401K |
| 2026-07-15 | LO FRANCIS | Chief People Officer | Sell | 106K | $22.59 | $2.4M | 231K |
| 2026-07-15 | LO FRANCIS | Chief People Officer | Exercise or conversion | 23K | $8.46 | $192K | 336K |
| 2026-07-15 | LO FRANCIS | Chief People Officer | Exercise or conversion | 24K | $12.14 | $287K | 314K |
| 2026-07-15 | LO FRANCIS | Chief People Officer | Exercise or conversion | 59K | $7.80 | $463K | 290K |
| 2026-07-02 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 147K | $22.45 | $3.3M | 1.0M |
| 2026-07-02 | ROBINS HARLAN S | Chief Scientific Officer | Sell | 239K | $21.74 | $5.2M | 1.2M |
| 2026-07-02 | LO FRANCIS | Chief People Officer | Sell | 45K | $22.59 | $1.0M | 231K |
| 2026-07-02 | LO FRANCIS | Chief People Officer | Exercise or conversion | 13K | $8.46 | $107K | 276K |
| 2026-07-02 | LO FRANCIS | Chief People Officer | Exercise or conversion | 13K | $12.14 | $153K | 263K |
| 2026-07-02 | LO FRANCIS | Chief People Officer | Exercise or conversion | 13K | $7.80 | $98K | 250K |
| 2026-07-01 | BOBULSKY SUSAN | Chief Commercial Officer, MRD | Sell | 487 | $22.00 | $11K | 406K |
| 2026-07-01 | LO FRANCIS | Chief People Officer | Sell | 42K | $22.50 | $951K | 238K |
| 2026-07-01 | LO FRANCIS | Chief People Officer | Sell | 9K | $22.18 | $194K | 280K |
| 2026-07-01 | LO FRANCIS | Chief People Officer | Exercise or conversion | 14K | $8.12 | $114K | 289K |
| 2026-07-01 | LO FRANCIS | Chief People Officer | Exercise or conversion | 5K | $3.99 | $19K | 275K |
| 2026-07-01 | LO FRANCIS | Chief People Officer | Exercise or conversion | 12K | $8.46 | $103K | 270K |
| 2026-07-01 | LO FRANCIS | Chief People Officer | Exercise or conversion | 3K | $12.14 | $40K | 258K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON42 Form 144 notices on file for ADPT worth $89.8M at the prices reported; 8 in the last 90 days worth $19.2M. Latest: SUSAN BOBULSKY filed on 2026-10-06 to sell 6,444 shares ($192K) from 2026-10-06.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-06 | SUSAN BOBULSKYOfficer | 6K | $192K | 0.004% | 2026-10-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-01 | JULIE RUBINSTEINOfficer | 380K | $11.0M | 0.238% | 2026-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-16 | FRANCIS LOOfficer | 142K | $3.8M | 0.089% | 2026-09-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-15 | SUSAN BOBULSKYOfficer | 1K | $30K | 0.001% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-26 | KATHERINE E OWENDirector | 10K | $250K | 0.006% | 2026-08-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-18 | ROBERT M HERSHBERGDirector | 31K | $748K | 0.019% | 2026-08-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | PETER NEUPERTDirector | 125K | $3.1M | 0.078% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-10 | SUSAN BOBULSKYOfficer | 3K | $75K | 0.002% | 2026-08-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-30 | SUSAN BOBULSKYOfficer | 1K | $29K | 0.001% | 2026-07-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-16 | SUSAN BOBULSKYOfficer | 5K | $115K | 0.003% | 2026-07-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-01 | FRANCIS LOOfficer | 199K | $4.3M | 0.125% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-01 | SUSAN BOBULSKYOfficer | 487 | $10K | 0.000% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-29 | SHARON BENZENOOfficer | 153K | $3.2M | 0.096% | 2026-06-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-26 | SHARON BENZENOOfficer | 13K | $261K | 0.008% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-25 | SUSAN BOBULSKYOfficer | 5K | $97K | 0.003% | 2026-06-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-25 | MICHELLE GRIFFINDirector | 52K | $1.0M | 0.033% | 2026-06-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-11 | SUSAN BOBULSKYOfficer | 5K | $85K | 0.003% | 2026-06-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-04 | SUSAN BOBULSKYOfficer | 11K | $176K | 0.007% | 2026-06-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-04 | FRANCIS LOOfficer | 42K | $673K | 0.026% | 2026-06-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-15 | PISKEL KYLEOfficer | 3K | $41K | 0.002% | 2026-05-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-08 | FRANCIS LOOfficer | 23K | $309K | 0.015% | 2026-04-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | BOBULSKY SUSANOfficer | 41K | $600K | 0.027% | 2026-03-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | BENZENO SHARONOfficer | 63K | $916K | 0.041% | 2026-03-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | ROBINS HARLAN SOfficer | 470K | $6.8M | 0.305% | 2026-03-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | RUBINSTEIN JULIEOfficer | 123K | $1.8M | 0.080% | 2026-03-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | PISKEL KYLEOfficer | 19K | $271K | 0.012% | 2026-03-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | ROBINS CHAD MOfficer, Director | 470K | $6.8M | 0.305% | 2026-03-11 | Morgan Stanley Smith Barney LLC |
| 2026-03-11 | FRANCIS LOOfficer | 31K | $444K | 0.020% | 2026-03-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-11 | MICHELLE GRIFFINDirector | 15K | $214K | 0.010% | 2026-03-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-10 | LO FRANCISOfficer | 38K | $626K | 0.025% | 2026-03-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-03 | JULIE RUBINSTEINOfficer | 1.2M | $19.5M | 0.784% | 2026-03-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-03 | MICHELLE GRIFFINDirector | 48K | $774K | 0.031% | 2026-03-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-12 | FRANCIS LOOfficer | 64K | $1.0M | 0.042% | 2026-01-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-12 | KYLE PISKELOfficer | 11K | $175K | 0.007% | 2026-01-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-15 | FRANCIS LOOfficer | 137K | $2.1M | 0.090% | 2025-12-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-10 | ROBERT M HERSHBERGDirector | 23K | $367K | 0.015% | 2025-12-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-04 | SHARON BENZENOOfficer | 13K | $216K | 0.008% | 2025-12-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-28 | KYLE PISKELOfficer | 163K | $3.2M | 0.107% | 2025-11-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-24 | BENZENO SHARONOfficer | 308K | $5.0M | 0.202% | 2025-11-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-21 | SHARON BENZENOOfficer | 309K | $5.0M | 0.202% | 2025-11-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-20 | SHARON BENZENOOfficer | 202K | $3.1M | 0.132% | 2025-11-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-19 | SHARON BENZENOOfficer | 96K | $1.3M | 0.063% | 2025-11-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON8 holders report 5% or more of ADPT in their latest filing, all on Schedule 13G (passive). The largest reported stake is VIKING GLOBAL INVESTORS LP at 18.8% of the class (29,993,708 shares), filed 2026-05-15 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-15 | 13G/Ano. 4 | VIKING GLOBAL INVESTORS LPpartnership | 30.0M | 18.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | HALVORSEN OLE ANDREASindividual | 30.0M | 18.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Shabet Rose Sharonindividual | 30.0M | 18.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | VIKING GLOBAL PERFORMANCE LLCother entity | 22.0M | 13.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Viking Global Equities Master Ltd.corporation | 21.6M | 13.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Viking Long Fund Master Ltd.corporation | 8.0M | 5.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Viking Long Fund GP LLCother entity | 8.0M | 5.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Viking Global Equities II LPpartnership | 440K | 0.3% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 6 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-01-21 | 13G/Ano. 3 | BlackRock, Inc.parent holding company | 12.0M | 7.9% | 2025-12-31 |
13F holders
Tracked managers holding ADPT at their latest 13F. JSON8 of the 30 tracked managers held ADPT at their latest 13F, $817.3M in total at quarter-end prices. Viking Global Investors is the largest at $643.4M (1.8% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 5 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Viking Global Investors | 2026-06-30 | 30.0M | $643.4M | 1.83% | 0 |
| D. E. Shaw & Co. | 2026-06-30 | 4.6M | $99.2M | 0.05% | +2.7M |
| ARK Investment Management | 2026-06-30 | 2.1M | $44.8M | 0.29% | -3K |
| Millennium Management | 2026-06-30 | 505K | $10.8M | 0.00% | -576K |
| AQR Capital Management | 2026-06-30 | 363K | $7.8M | 0.00% | -122K |
| Renaissance Technologies | 2026-06-30 | 303K | $6.5M | 0.01% | +63K |
| Citadel Advisors | 2026-06-30 | 181K | $3.9M | 0.00% | -182K |
| Bridgewater Associates | 2026-06-30 | 40K | $860K | 0.00% | -50K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Adaptive Biotechnologies reported revenue of $71.6M, up 21.5% from the same quarter a year earlier, and net loss of $39.8M (-0.25 diluted EPS). In FY 2025 it generated -$46.0M of operating cash flow. As of 2026-06-30, cash was $169.9M against $0 of debt.
- Cash
- $169.9M
- Debt
- $0
- Equity
- $142.9M
- Total assets
- $640.7M
- Shares outstanding
- 159,595,842
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $71.6M | -$39.8M | -55.6% | -0.25 |
| Q1 FY 2026 | 2026-03-31 | $70.9M | -$20.0M | -28.3% | -0.13 |
| Q4 FY 2025derived | 2025-12-31 | $71.7M | -$13.6M | -18.9% | n/a |
| Q3 FY 2025 | 2025-09-30 | $94.0M | $9.5M | 10.2% | 0.06 |
| Q2 FY 2025 | 2025-06-30 | $58.9M | -$25.6M | -43.5% | -0.17 |
| Q1 FY 2025 | 2025-03-31 | $52.4M | -$29.9M | -56.9% | -0.20 |
| Q4 FY 2024derived | 2024-12-31 | $47.5M | -$33.7M | -71.0% | n/a |
| Q3 FY 2024 | 2024-09-30 | $46.4M | -$32.1M | -69.1% | -0.22 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $277.0M | -$59.5M | -$46.0M | $3.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $179.0M | -$159.5M | -$95.2M | $3.7M | n/a | n/a |
| FY 2023 | 2023-12-31 | $170.3M | -$225.3M | -$156.3M | $10.7M | n/a | n/a |
| FY 2022 | 2022-12-31 | $185.3M | -$200.2M | -$183.9M | $16.3M | n/a | n/a |
| FY 2021 | 2021-12-31 | $154.3M | -$207.3M | -$192.7M | $61.7M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Adaptive Biotechnologies in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Adaptive Biotechnologies (ADPT), SEC CIK 1478320, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-24.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-06.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-15.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-29.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-26.JSON and CSV
- Company record
- EDGAR filing index for CIK 1478320Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
Datasets
Frequently Asked Questions
How much of ADPT is sold short?
11,991,988 shares were held short at the 2026-10-15 settlement, 5.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ADPT's daily short volume?
On 2026-10-28, 515,055 of the 1,194,949 ADPT shares reported to FINRA were sold short, 43.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ADPT have fails to deliver?
The SEC's latest file shows 15 ADPT shares failed to deliver at settlement 2026-09-24. Fails are reported per settlement date and published twice a month with a lag.
Are ADPT insiders buying or selling?
Insiders at ADPT reported 48 open-market sells worth $28.9M in the last 90 days and no open-market buys. Latest filing: RUBINSTEIN JULIE (President and COO) on 2026-10-26.
Have ADPT insiders filed to sell?
42 Form 144 notices on file for ADPT worth $89.8M at the prices reported; 8 in the last 90 days worth $19.2M. Latest: SUSAN BOBULSKY filed on 2026-10-06 to sell 6,444 shares ($192K) from 2026-10-06.
Who owns 5% or more of ADPT?
8 holders report 5% or more of ADPT in their latest filing, all on Schedule 13G (passive). The largest reported stake is VIKING GLOBAL INVESTORS LP at 18.8% of the class (29,993,708 shares), filed 2026-05-15 for an event on 2026-03-31.
What did ADPT report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Adaptive Biotechnologies reported revenue of $71.6M, up 21.5% from the same quarter a year earlier, and net loss of $39.8M (-0.25 diluted EPS). In FY 2025 it generated -$46.0M of operating cash flow. As of 2026-06-30, cash was $169.9M against $0 of debt.
Which tracked 13F managers own ADPT?
8 of the 30 tracked 13F managers held ADPT shares at their latest filing, $817.3M in all. The largest: Andreas Halvorsen's Viking Global Investors (30.0M shares, $643.4M), D. E. Shaw & Co. (4.6M shares, $99.2M), Cathie Wood's ARK Investment Management (2.1M shares, $44.8M), Izzy Englander's Millennium Management (505K shares, $10.8M), Cliff Asness's AQR Capital Management (363K shares, $7.8M), Renaissance Technologies (303K shares, $6.5M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.